Compare BridgeBio Pharma Inc (BBIO) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Omnicom Group Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Omnicom Group Inc. trades at $85.74 (market cap $23.58B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 3.72% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | OMC | |
|---|---|---|
Market Cap | $16.36B | $23.58B |
Sector | Health | Media |
52-Week High | $90.17 | $86.22 |
52-Week Low | $47.29 | $67.27 |
Enterprise Value | $18.14B | $31.66B |
Dividend Yield | — | 3.72% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
